Castle Biosciences Launches Test to Guide Atopic Dermatitis Treatment Selection
The gene expression test is designed to identify patients more likely to respond to JAK inhibitors versus Th2-targeted therapies.
The gene expression test is designed to identify patients more likely to respond to JAK inhibitors versus Th2-targeted therapies.
The multiplex immunoassay measures autoantibodies to the 14-3-3eta protein and aims to reduce diagnostic delays that currently average seven to 10 years.
UCLA Health researchers find cell-free DNA combined with machine learning can distinguish ALS from other neurological conditions.
The mass spectrometry-based assay achieved 100% sensitivity in detecting patients who later progressed to cancer in a blinded cohort study.
Electrochemical biosensor aims to simultaneously detect HIV, Hepatitis B, and Hepatitis C in resource-limited settings using RNA-level identification.
Researchers urge clinicians to integrate lipid management into prenatal care to mitigate elevated obstetric complications and cardiovascular risks.
From rising demand for comprehensive IgE profiles to the emergence of molecular allergen diagnostics, laboratories are central to how clinicians prepare for and manage September’s asthma spike.
Study of more than 13,000 individuals demonstrates improved precision for emergency department triage and patient outcomes.
Roche's Elecsys pTau181 assay gives clinical labs a key role in the initial evaluation of cognitive decline, helping to rule out amyloid pathology earlier in the diagnostic process.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
TriVerity system demonstrated high sensitivity and specificity across more than 1,200 patients in pivotal SEPSIS-SHIELD trial.